Oxeia Biopharmaceuticals
Rest is not enough

In The News

CBS Sports Radio, March 20, 2019 San Francisco 49ers cornerback and Oxeia board member Richard Sherman stops by the Tiki and Tierney Show to talk about concussions and Oxeia's research.
San Francisco Chronicle, February 19, 2019 SF 49er and Oxeia board member Richard Sherman speaks his mind about the NFL's concussion policy in his San Francisco Chronicle op-ed. Tells readers concussion medicines are under development.
S+P, December 18, 2018 Leading market analysis publication interviews Oxeia CEO Michael Wyard about how Oxeia works, clinical trials, and anticipated market.
San Diego Business Journal, December 10, 2018 Oxeia Leading the Pack on Potential Concussion Treatments. Oxeia's co-founder and chief business officer, Kartik Shah explains that, "Oxeia's drug (OXE-103) promotes the generation of new synapses, which could play a role in connectivity and cognition." Oxeia is raising $3million for mid-stage human trials, while others in the space are in the preclinical stage. According to Shah, "OXE-103 is targeting multiple pathways, upping the chances of success."
Boston Globe, November 23, 2018 Oxeia is one of handful of startups experimenting with drugs that could treat concussions.
September 6, 2017 Oxeia Biopharmaceuticals, Inc. Announces Appointment of Dr. Michael Wyand as Chief Executive Officer
August 27, 2017 FiercePharma Article: Richard Sherman Joins Oxeia Advisory Board
August 23, 2017 Richard Sherman, NFL All-Pro, Joins Oxeia Biopharmaceuticals Advisory Board
August 2, 2017 Oxeia Biopharmaceuticals Announces Clinical Advancement of Concussion Treatment
December 14, 2016 Christopher Nowinski Joins Oxeia Biopharmaceuticals Advisory Board
January 21, 2016 Oxeia Biopharmaceuticals, Inc. Advancing Development of OXE-103 for the Treatment of Concussions